Catalyst Pharmaceutical CPRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $149.39M-2.1% | $152.61M+2.8% | $148.39M+1.2% | $146.56M+3.6% | $141.42M-0.3% | ||
| $14.48M-44.5% | $26.07M+15.1% | $22.65M+9.9% | $20.61M+15.1% | $17.91M-17.2% | ||
| $134.92M+6.6% | $126.54M+0.6% | $125.74M-0.2% | $125.95M+2.0% | $123.51M+2.8% | ||
| 90.3%+7.4pp | 82.9%-1.8pp | 84.7%-1.2pp | 85.9%-1.4pp | 87.3%+2.6pp | ||
| $2.66M+47.3% | $1.81M-32.0% | $2.66M-39.0% | $4.36M+12.1% | $3.89M+2.3% | ||
| $49.32M-7.7% | $53.42M+12.5% | $47.47M+3.3% | $45.95M-2.1% | $46.91M+6.2% | ||
| $73.23M+18.4% | $61.85M-6.7% | $66.27M0.0% | $66.3M+4.6% | $63.37M+0.8% | ||
| 49%+8.5pp | 40.5%-4.1pp | 44.7%-0.6pp | 45.2%+0.4pp | 44.8%+0.5pp | ||
| $11M+9.4% | $10.06M+111% | $4.77M+59.2% | $3M-62.2% | $7.92M-30.2% | ||
| $84.23M+17.1% | $71.9M+1.2% | $71.04M+2.5% | $69.29M-2.8% | $71.29M-3.9% | ||
| $20.5M+6.7% | $19.2M+5.2% | $18.25M+6.2% | $17.19M+18.1% | $14.55M-20.3% | ||
| $63.73M+20.9% | $52.7M-0.2% | $52.78M+1.3% | $52.11M-8.2% | $56.74M+1.4% | ||
| 42.7%+8.1pp | 34.5%-1.0pp | 35.6%0.0pp | 35.6%-4.6pp | 40.1%+0.7pp | ||
| $0.50+22.0% | $0.41-2.4% | $0.42+2.4% | $0.41-8.9% | $0.45+2.3% | ||
| $0.52+20.9% | $0.430.0% | $0.430.0% | $0.43-8.5% | $0.47+2.2% | ||
| 126.9M-0.3% | 127.3M+0.1% | 127.1M-0.4% | 127.5M+0.5% | 127M+1.6% | ||
| 122.3M0.0% | 122.3M-0.3% | 122.6M+0.4% | 122.2M+0.6% | 121.5M+2.5% | ||
| $9.7M+2.5% | $9.47M+1.3% | $9.34M0.0% | $9.34M0.0% | $9.35M0.0% | ||
| $63.74M+21.0% | $52.7M-0.1% | $52.75M+1.1% | $52.16M-7.9% | $56.66M+1.2% | ||
| $76.16M-16.1% | $90.77M+10.5% | $82.13M+2.3% | $80.27M+2.8% | $78.05M-1.2% | ||
| $8K— | $0+100% | -$31K-165% | $48K+159% | -$81K-227% | ||
| $11M+9.4% | $10.06M+111% | $4.77M+59.2% | $3M-62.2% | $7.92M-30.2% | ||
| $149.39M-2.1% | $152.61M+2.8% | $148.39M+1.2% | $146.56M+3.6% | $141.42M-0.3% | ||
| $73.23M+18.4% | $61.85M-6.7% | $66.27M0.0% | $66.3M+4.6% | $63.37M+0.8% | ||
| $83.01M+16.3% | $71.38M-5.7% | $75.68M-0.1% | $75.76M+4.0% | $72.83M+0.7% | ||
| $83.01M+16.3% | $71.38M-5.7% | $75.68M-0.1% | $75.76M+4.0% | $72.83M+0.7% | ||
| 55.6%+8.8pp | 46.8%-4.2pp | 51%-0.7pp | 51.7%+0.2pp | 51.5%+0.5pp | ||
| $73.23M+18.4% | $61.85M-6.7% | $66.27M0.0% | $66.3M+4.6% | $63.37M+0.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Catalyst Pharmaceutical's profit margins?
- Gross margin is 86.0% and operating margin is 44.8%, with a 37.1% net margin.
- Where does Catalyst Pharmaceutical's income statement data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.